Our study found a significant decrease in IL-6, IL-1β, IL-17A, and TNF-α levels in mice after L.p CMU-Pb-L5 intervention, indicating that L.p CMU-Pb-L5 intervention could reduce inflammatory cytokine levels in vivo and slow CRC tumor growth. The gene discussed is IL1B; the disease is colorectal carcinoma.